about
Genomic alterations in sporadic synchronous primary breast cancer using array and metaphase comparative genomic hybridization.The effects of timing of fine needle aspiration biopsies on gene expression profiles in breast cancers.Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cellsThe role of stromal factors in breast tumorigenicity.Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimensProteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival.Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populations.Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.Limited tissue fixation times and whole genomic amplification do not impact array CGH profilesClose or positive resection margins are not associated with an increased risk of chest wall recurrence in women with DCIS treated by mastectomy: a population-based analysisMitochondrial D310 mutations in the early development of breast cancerThe use of whole genome amplification in the study of human disease.Changes of collagen ultrastructure in breast cancer tissue determined by second-harmonic generation double Stokes-Mueller polarimetric microscopy.Incidence of breast cancer in patients with pure flat epithelial atypia diagnosed at core-needle biopsy of the breast.Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis.Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast.Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.Molecular Profiling and Significance of Circulating Tumor Cell Based Genetic Signatures.Identification of genomic signatures in circulating tumor cells from breast cancer.Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo.Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion.Quantitative detection of circulating epithelial cells by Q-RT-PCR.Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program.Digital Compared with Screen-Film Mammography: Measures of Diagnostic Accuracy among Women Screened in the Ontario Breast Screening Program.Digital versus screen-film mammography: impact of mammographic density and hormone therapy on breast cancer detection.Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients.Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation.Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis.Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study.Partial characterization of the enhanced survival of female NZB/W mice treated with lithium chloride.TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation.Loss of ALX4 expression in epithelial cells and adjacent stromal cells in breast cancer.
P50
Q33289495-BC0C7A3A-75ED-46CD-B7E4-EF9BFBEFAA85Q33372939-4732CAD0-0D21-45CE-A46A-3B3B38B580AEQ33637896-3C307696-DE98-496D-B66D-E3DB5F413664Q33703599-64819B70-AB0F-4693-A1C1-579F60C683E9Q33934517-B6511AF8-7474-44C2-950D-6D2D98A0ACA3Q34170410-CC629DAE-5698-4071-A36B-B144B8134351Q34485047-6D6D8DA5-E222-4CDC-AF36-0EC4EB1DF74DQ35238162-CFA034A1-32D6-428B-964A-E1DE1C2B710CQ35769785-696D1EF8-AA4A-4C0C-9234-161FFC40DF19Q35836973-C50EB7BF-4AF4-4D79-877D-5FAA86CE5986Q35927170-8F23516A-4EE8-47C2-9476-5D1BBB858019Q35961432-4FABE883-4E37-4CEA-9C78-D2D14F46DFF3Q36199041-36E749E8-DF31-4357-97CA-442FC1EEAEDAQ38052016-0293F186-904B-4219-8BB8-CB8DDE2CC19FQ38086079-BA2024F5-46B2-4B91-ACEF-4E30A4A378F7Q38109473-29C198E9-8813-45F6-A029-25125FB4BC5DQ38249136-D1A2725F-CD1F-4C30-89AA-AE4AA45802E3Q38419887-D37054D4-6A7C-46B0-BDF4-8569E8DC4B66Q38454142-FA3D8ED2-E90B-4275-B36B-741B42F29824Q38676889-414EE212-FB38-425D-A8DB-EC72AFCB3875Q38926497-1ABEEEFB-E8A8-4AB2-93A6-87D2EC4241F3Q39324990-4DF80412-4A49-4256-847F-A7DDD4C13682Q39949435-7FFB47C1-0F7E-47EA-AF89-36DEA1767A14Q40064550-88A21767-9E1F-4E41-AF72-514F4A7D98F4Q40161469-8A34827F-9CA9-4D05-B4B0-1050A8D37B3BQ40213767-DB9852E8-93A7-4A6D-8B8D-FC07D02FD9FBQ40310351-45F1F684-F347-4EFF-89BE-D345D2D5F4F9Q40326420-30AF9388-5EB5-44AB-9376-80193A211AD5Q40509140-59C2BC2E-E034-4EFC-8142-2F73B57C44E3Q41435904-71392452-AC44-4A5A-9822-33200DD525F5Q41522811-02F5C5F7-C6C8-4E65-BDE7-17D73DC8E476Q42390872-008BA393-1FFC-406D-AA99-F1079AF4F44FQ42476869-559687E7-E291-4B62-97A0-EE588DC24A48Q42808065-6C23CECA-0F8C-4F25-8228-4E2A64CF6ECDQ43016990-1F7833BF-A1A0-4996-B103-E7C61EE167D1Q43183453-B5587B83-5D55-49CA-B3CC-5BCBFD7FAB6DQ44517294-9074D308-E055-4052-8B8D-31E785025B97Q44681842-EACA9A54-4BA2-4E93-8F85-E0E71F2C8FD2Q45086703-B6144742-8350-481D-9037-797439780F05Q46445640-C7C9E70C-347F-4C07-9D77-02BBDA03567E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Susan J. Done
@ast
Susan J. Done
@en
Susan J. Done
@es
Susan J. Done
@nl
Susan J. Done
@sl
type
label
Susan J. Done
@ast
Susan J. Done
@en
Susan J. Done
@es
Susan J. Done
@nl
Susan J. Done
@sl
prefLabel
Susan J. Done
@ast
Susan J. Done
@en
Susan J. Done
@es
Susan J. Done
@nl
Susan J. Done
@sl
P106
P1153
7006099450
P21
P31
P496
0000-0002-1770-988X